CLINICAL// TRANSLATIONAL

IDENTIFYING BIOMARKERS
to ASSESS PEDIATRIC
SPINAL INJURY
DIAGNOSING AND ASSESSING SPINAL CORD INJURY (SCI)
in children and adolescents has long been a
challenging task, as has been the application of
relevant and established outcomes measures
for these patients. “In adults, the neurological
consequence of SCI is determined by physically
examining 56 sites on the patient’s body—
examinations that require full participation and
cognitive awareness,” explains Mary Jane (MJ)
Mulcahey, PhD, professor of occupational therapy.
“But we showed in a study of 236 children with SCI
that children younger than six years—and some
up to 10 years old—are not able to participate
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effectively. The clinical assessment of SCI is also
challenging with adults who have brain injury or are
in a coma or medical-induced sedation. We need to
develop imaging biomarkers that tell us—regardless
of a patient’s age or mental capacity—the precise
extent of damage.”
With a team of biostatisticians, engineers, neuroradiologists, neuroscientists, occupational therapists
and physicists, Dr. Mulcahey has been developing
and validating spinal cord imaging biomarkers
and testing the feasibility of neuroimaging to
predict SCI outcomes. Their proof-of-concept
study employed diffusion tensor imaging (DTI) to

MJ Mulcahey, PhD, met Miki Greenstein, pictured, soon after
he had a spinal cord injury at the age of 13. She has worked
with him for 20 years now, and he is a frequent participant
in her research studies. Here, she and student Samantha
Burke work with Miki on a SaeboReJoyce rehabilitation
workstation that helps with arm and hand training.

This work could fill a major
gap in pediatric care.
Mary Jane Mulcahey, PhD
Professor of Occupational Therapy

effectively analyze both direct and indirect spinal
cord damage in children and youth between
birth and 21 years old at the time of injury.
Since then, funded by the NIH, the team has
successfully employed an expanding array of
imaging technologies to visualize in detail the
original injury and subsequent pathologies.
Those techniques have included the spinal
cord cross-sectional area, which offers a
structural biomarker for spinal cord atrophy
and related pathology; and fiber tractography,
which provides a 3D reconstruction of
neural tracts using data collected by DTI.
Throughout the studies, the researchers have
correlated biomarker-focused discoveries and
observations of patients’ clinical presentation.
Now, they are ready to take the important next
step: developing and testing projections for
individual patients, based on comprehensive
imaging studies of newly injured patients
and multi-year tracking of their progress.
“To our knowledge, we are the only group seeking
to define and validate pediatric SCI imaging
biomarkers,” Dr. Mulcahey observes. “We are
excited about this work because it could fill a
major gap in pediatric care—and, potentially,
inform better treatment of adult SCI too.” 

31

